Last reviewed · How we verify

TT-00420 (tinengotinib) — Competitive Intelligence Brief

TT-00420 (tinengotinib) (TT-00420 (tinengotinib)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-targeted tyrosine kinase inhibitor. Area: Oncology.

phase 3 Multi-targeted tyrosine kinase inhibitor VEGFR, FGFR, and other receptor tyrosine kinases Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TT-00420 (tinengotinib) (TT-00420 (tinengotinib)) — TransThera Sciences (Nanjing), Inc.. Tinengotinib is a tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor growth and angiogenesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TT-00420 (tinengotinib) TARGET TT-00420 (tinengotinib) TransThera Sciences (Nanjing), Inc. phase 3 Multi-targeted tyrosine kinase inhibitor VEGFR, FGFR, and other receptor tyrosine kinases
Sunitinib Malate (SU011248) Sunitinib Malate (SU011248) H. Lee Moffitt Cancer Center and Research Institute marketed Multi-targeted tyrosine kinase inhibitor VEGFR, PDGFR, KIT, FLT3
pazopanib or guideline conform chemotherapy pazopanib or guideline conform chemotherapy GWT-TUD GmbH marketed Multi-targeted tyrosine kinase inhibitor VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, c-Kit
Lenvatinib + losartan Lenvatinib + losartan Second Affiliated Hospital of Xi'an Jiaotong University marketed Multi-targeted tyrosine kinase inhibitor + angiotensin II receptor antagonist FGFR, VEGFR, RET (lenvatinib); AT1 receptor (losartan)
Letybo® Letybo® Yuvell marketed FLT3 inhibitor / multi-targeted tyrosine kinase inhibitor FLT3, JAK2
Anlotinib hydrochloride capsules Anlotinib hydrochloride capsules Chia Tai Tianqing Pharmaceutical Group Co., Ltd. marketed Multi-targeted tyrosine kinase inhibitor VEGFR, FGFR, PDGFR, c-Kit, RET
Sunitinib (Sutent) Sunitinib (Sutent) Sponsor GmbH marketed Multi-targeted tyrosine kinase inhibitor VEGFR, PDGFR, KIT, FLT3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-targeted tyrosine kinase inhibitor class)

  1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
  2. Exelixis · 2 drugs in this class
  3. H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class
  4. Merck Sharp & Dohme LLC · 1 drug in this class
  5. National Cancer Institute, Naples · 1 drug in this class
  6. Sponsor GmbH · 1 drug in this class
  7. Sun Yat-sen University · 1 drug in this class
  8. TransThera Sciences (Nanjing), Inc. · 1 drug in this class
  9. Advenchen Laboratories Nanjing Ltd. · 1 drug in this class
  10. University of Wisconsin, Madison · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TT-00420 (tinengotinib) — Competitive Intelligence Brief. https://druglandscape.com/ci/tt-00420-tinengotinib. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: